acral melanomanivolumabipilimumabpembrolizumabSheffield Teaching Hospital NHS TrustUniversity College London HospitalNottingham Hospitals University TrustSouthampton General HospitalRoyal Preston HospitaliSCIB1++2 more
… months, following exclusion of two non-protocol patients, with acral melanoma and active brain metastases.Cohort 3: 64.5% (20/31) and 80.6% (…